缓解与低疾病活动度可预防系统性红斑狼疮患者的损伤累积:来自系统性红斑狼疮国际协作组(SLICC)起始队列的研究结果
该研究基于多国起始狼疮队列中1652例患者,定义五种互斥疾病活动状态,采用广义估计方程负二项回归分析。结果显示,无治疗缓解、治疗中缓解、LDA-TC和mLLDAS均与较低的损伤累积概率相关,且校正混杂因素后仍成立。
要点
- 无治疗缓解、治疗中缓解、LDA-TC和mLLDAS均与较低的损伤累积概率相关。
- 无治疗缓解的IRR=0.75(95%CI 0.70-0.81),治疗中缓解的IRR=0.68(95%CI 0.62-0.75)。
- LDA-TC的IRR=0.79(95%CI 0.68-0.92),mLLDAS的IRR=0.76(95%CI 0.65-0.89)。
核心结论
- 治疗中缓解、无治疗缓解、LDA-TC和mLLDAS均与较少的损伤累积相关,即使校正可能的混杂因素和效应修饰因素后仍成立。
研究设计与样本
- 研究纳入来自纵向多国起始狼疮队列、有至少2次年度评估的患者,共1652例,其中女性1464例(88.6%),诊断时平均年龄34.2岁(SD 13.4),平均随访时间7.7年(SD 4.8)。
- 定义了五种互斥的疾病活动状态:无治疗缓解(cSLEDAI-2K=0,未用泼尼松或免疫抑制剂)、治疗中缓解(cSLEDAI-2K=0,泼尼松≤5 mg/天和/或维持性免疫抑制剂)、LDA-TC(cSLEDAI-2K≤2,未用泼尼松或免疫抑制剂)、mLLDAS(SLEDAI-2K=4,无主要器官/系统活动、无新发疾病活动,泼尼松≤7.5 mg/天和/或维持性免疫抑制剂)、活动期(其余所有访视)。
- 每次访视仅采用最严格的定义,所有状态均允许使用抗疟药;采用广义估计方程负二项回归模型进行单变量和多变量分析,时变协变量与疾病活动状态在同一次年度访视确定,而SDI在随后的访视确定。
主要发现
- 无治疗缓解、治疗中缓解、LDA-TC和mLLDAS(每增加25%)均与较低的损伤累积概率相关:无治疗缓解IRR=0.75(95%CI 0.70-0.81);治疗中缓解IRR=0.68(95%CI 0.62-0.75);LDA-TC IRR=0.79(95%CI 0.68-0.92);mLLDAS IRR=0.76(95%CI 0.65-0.89)。
关键数值与推荐
- 无治疗缓解定义:cSLEDAI-2K=0,未用泼尼松或免疫抑制剂。
- 治疗中缓解定义:cSLEDAI-2K=0,泼尼松≤5 mg/天和/或维持性免疫抑制剂。
- LDA-TC定义:cSLEDAI-2K≤2,未用泼尼松或免疫抑制剂。
- mLLDAS定义:SLEDAI-2K=4,无主要器官/系统活动、无新发疾病活动,泼尼松≤7.5 mg/天和/或维持性免疫抑制剂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the independent impact of different definitions of remission and low disease activity (LDA) on damage accrual. METHODS: Patients with ≥2 annual assessments from a longitudinal multinational inception lupus cohort were studied. Five mutually exclusive disease activity states were defined: remission off-treatment: clinical Systemic Lupus Erythematosus Disease Activity Index (cSLEDAI)-2K=0, without prednisone or immunosuppressants; remission on-treatment: cSLEDAI-2K score=0, prednisone ≤5 mg/day and/or maintenance immunosuppressants; low disease activity Toronto cohort (LDA-TC): cSLEDAI-2K score of ≤2, without prednisone or immunosuppressants; modified lupus low disease activity (mLLDAS): Systemic Lupus Erythematosus Disease Activity Index-2K score of 4 with no activity in major organ/systems, no new disease activity, prednisone ≤7.5 mg/day and/or maintenance immunosuppressants; active: all remaining visits. Only the most stringent definition was used per visit. Antimalarials were allowed in all. The proportion of time that patients were in a specific state at each visit since cohort entry was determined. Damage accrual was ascertained with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Univariable and multivariable generalised estimated equation negative binomial regression models were used. Time-dependent covariates were determined at the same annual visit as the disease activity state but the SDI at the subsequent visit. RESULTS: There were 1652 patients, 1464 (88.6%) female, mean age at diagnosis 34.2 (SD 13.4) years and mean follow-up time of 7.7 (SD 4.8) years. Being in remission off-treatment, remission on-treatment, LDA-TC and mLLDAS (per 25% increase) were each associated with a lower probability of damage accrual (remission off-treatment: incidence rate ratio (IRR)=0.75, 95% CI 0.70 to 0.81; remission on-treatment: IRR=0.68, 95% CI 0.62 to 0.75; LDA: IRR=0.79, 95% CI 0.68 to 0.92; and mLLDAS: IRR=0.76, 95% CI 0.65 to 0.89)). CONCLUSIONS: Remission on-treatment and off-treatment, LDA-TC and mLLDAS were associated with less damage accrual, even adjusting for possible confounders and effect modifiers.
引用
- Ugarte-Gil MF, Hanly J, Urowitz M, et al. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022. PMID: 35944946. doi:10.1136/ard-2022-222487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。